factuality_value
stringclasses 7
values | predicat@xml:space
stringclasses 1
value | predicat@charOffset
stringlengths 3
9
| predicat@headOffset
stringlengths 3
9
| predicat@id
stringclasses 206
values | predicat@text
stringlengths 2
124
| predicat@type
stringclasses 29
values | predicat@charOffsetMin
int64 0
3.96k
| predicat@charOffsetMax
int64 6
3.97k
| subject@xml:space
stringclasses 1
value | subject@charOffset
stringlengths 3
9
| subject@headOffset
stringlengths 3
9
| subject@id
stringclasses 197
values | subject@text
stringlengths 2
49
| subject@type
stringclasses 72
values | subject@charOffsetMin
int64 0
3.98k
| subject@charOffsetMax
int64 3
4k
| object@xml:space
stringclasses 1
value | object@charOffset
stringlengths 3
9
| object@headOffset
stringlengths 3
9
| object@id
stringclasses 198
values | object@text
stringlengths 2
53
| object@type
stringclasses 73
values | object@charOffsetMin
int64 0
3.93k
| object@charOffsetMax
int64 4
3.94k
| id
stringclasses 58
values | raw_sent_text
stringlengths 20
749
| sent_charOffset
stringlengths 4
9
| sent_charOffsetMin
int64 0
3.88k
| sent_charOffsetMax
int64 26
4.2k
| formated_sentence
stringlengths 34
768
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fact | preserve | 1290-1293 | 1290-1293 | T80 | for | TREATS | 1,290 | 1,293 | preserve | 1241-1254 | 1241-1254 | T73 | streptokinase | AminoAcidPeptideOrProtein | 1,241 | 1,254 | preserve | 1294-1302 | 1294-1302 | T76 | patients | PatientOrDisabledGroup | 1,294 | 1,302 | A2 | RESULTS: In the absence of streptokinase resistance, streptokinase is a cost effective strategy for patients with suspected myocardial infarction, even when the expected mortality is low. | 1182-1387 | 1,182 | 1,387 | RESULTS: In the absence of streptokinase resistance, @SUBJECT$ is a cost effective strategy @PREDICAT$ @OBJECT$ with suspected myocardial infarction, even when the expected mortality is low. |
Fact | preserve | 1303-1307 | 1303-1307 | T81 | with | PROCESS_OF | 1,303 | 1,307 | preserve | 1318-1339 | 1329-1339 | T77 | myocardial infarction | DiseaseOrSyndrome | 1,318 | 1,339 | preserve | 1294-1302 | 1294-1302 | T76 | patients | PatientOrDisabledGroup | 1,294 | 1,302 | A4 | RESULTS: In the absence of streptokinase resistance, streptokinase is a cost effective strategy for patients with suspected myocardial infarction, even when the expected mortality is low. | 1182-1387 | 1,182 | 1,387 | RESULTS: In the absence of streptokinase resistance, streptokinase is a cost effective strategy for @OBJECT$ @PREDICAT$ suspected @SUBJECT$ , even when the expected mortality is low. |
Fact | preserve | 93-100 | 93-100 | T6 | treated | TREATS | 93 | 100 | preserve | 106-119 | 106-119 | T5 | streptokinase | AminoAcidPeptideOrProtein | 106 | 119 | preserve | 67-75 | 67-75 | T4 | patients | PatientOrDisabledGroup | 67 | 75 | A5 | Potential cost effectiveness of tissue plasminogen activator among patients previously treated with streptokinase. | 0-120 | 0 | 120 | Potential cost effectiveness of tissue plasminogen activator among @OBJECT$ previously @PREDICAT$ with @SUBJECT$ . |
Fact | preserve | 1290-1293 | 1290-1293 | T80 | for | TREATS | 1,290 | 1,293 | preserve | 1241-1254 | 1241-1254 | T73 | streptokinase | AminoAcidPeptideOrProtein | 1,241 | 1,254 | preserve | 1318-1339 | 1329-1339 | T77 | myocardial infarction | DiseaseOrSyndrome | 1,318 | 1,339 | A6 | RESULTS: In the absence of streptokinase resistance, streptokinase is a cost effective strategy for patients with suspected myocardial infarction, even when the expected mortality is low. | 1182-1387 | 1,182 | 1,387 | RESULTS: In the absence of streptokinase resistance, @SUBJECT$ is a cost effective strategy @PREDICAT$ patients with suspected @OBJECT$ , even when the expected mortality is low. |
Fact | preserve | 2217-2219 | 2217-2219 | T141 | in | TREATS | 2,217 | 2,219 | preserve | 2212-2216 | 2212-2216 | T123 | t-PA | AminoAcidPeptideOrProtein | 2,212 | 2,216 | preserve | 2227-2235 | 2227-2235 | T124 | patients | PatientOrDisabledGroup | 2,227 | 2,235 | A7 | CONCLUSIONS: This analysis shows that using t-PA in patients previously treated with streptokinase is a cost effective strategy. | 2168-2303 | 2,168 | 2,303 | CONCLUSIONS: This analysis shows that using @SUBJECT$ @PREDICAT$ @OBJECT$ previously treated with streptokinase is a cost effective strategy. |
Fact | preserve | 921-933 | 921-933 | T55 | administered | ADMINISTERED_TO | 921 | 933 | preserve | 870-883 | 870-883 | T51 | streptokinase | AminoAcidPeptideOrProtein | 870 | 883 | preserve | 967-975 | 967-975 | T54 | patients | PatientOrDisabledGroup | 967 | 975 | A8 | It was assumed that streptokinase would be clinically ineffective when administered to streptokinase-resistant patients. | 844-976 | 844 | 976 | It was assumed that @SUBJECT$ would be clinically ineffective when @PREDICAT$ to streptokinase-resistant @OBJECT$ . |
Fact | preserve | 1153-1161 | 1153-1161 | T68 | compared | compared_with | 1,153 | 1,161 | preserve | 1148-1152 | 1148-1152 | T66 | t-PA | AminoAcidPeptideOrProtein | 1,148 | 1,152 | preserve | 1167-1180 | 1167-1180 | T67 | streptokinase | AminoAcidPeptideOrProtein | 1,167 | 1,180 | A10 | Sensitivity analyses were performed varying the baseline mortality, the proportion of patients resistant to streptokinase and the absolute survival benefit of t-PA compared with streptokinase. | 977-1181 | 977 | 1,181 | Sensitivity analyses were performed varying the baseline mortality, the proportion of patients resistant to streptokinase and the absolute survival benefit of @SUBJECT$ @PREDICAT$ with @OBJECT$ . |
Fact | preserve | 316-337 | 330-337 | T19 | streptokinase therapy | USES | 316 | 337 | preserve | 316-329 | 316-329 | T16 | streptokinase | AminoAcidPeptideOrProtein | 316 | 329 | preserve | 316-329 | 316-329 | T16 | streptokinase | AminoAcidPeptideOrProtein | 316 | 329 | A13 | BACKGROUND: A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat streptokinase therapy. | 121-338 | 121 | 338 | BACKGROUND: A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat @OBJECT$ @SUBJECT$ @PREDICAT$ . |
Fact | preserve | 525-529 | 525-529 | T34 | with | USES | 525 | 529 | preserve | 515-524 | 515-524 | T30 | treatment | TherapeuticOrPreventiveProcedure | 515 | 524 | preserve | 537-550 | 537-550 | T31 | streptokinase | AminoAcidPeptideOrProtein | 537 | 550 | A16 | Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous treatment with streptokinase. | 339-551 | 339 | 551 | Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 438-442 | 438-442 | T33 | with | PROCESS_OF | 438 | 442 | preserve | 459-469 | 459-469 | T25 | infarction | PathologicFunction | 459 | 469 | preserve | 429-437 | 429-437 | T23 | patients | PatientOrDisabledGroup | 429 | 437 | A17 | Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous treatment with streptokinase. | 339-551 | 339 | 551 | Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to @OBJECT$ @PREDICAT$ recurrent @SUBJECT$ presenting more than four days from previous treatment with streptokinase. |
Fact | preserve | 316-337 | 330-337 | T18 | streptokinase therapy | ISA | 316 | 337 | preserve | 316-329 | 316-329 | T16 | streptokinase | AminoAcidPeptideOrProtein | 316 | 329 | preserve | 330-337 | 330-337 | T17 | therapy | TherapeuticOrPreventiveProcedure | 330 | 337 | A19 | BACKGROUND: A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat streptokinase therapy. | 121-338 | 121 | 338 | BACKGROUND: A major limitation of streptokinase is the development and persistence of problematic neutralizing antibodies that have the potential to limit the effectiveness of repeat @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Probable | preserve | 413-425 | 413-425 | T32 | administered | ADMINISTERED_TO | 413 | 425 | preserve | 352-391 | 382-391 | T21 | tissue-type plasminogen activator | AminoAcidPeptideOrProtein | 352 | 391 | preserve | 429-437 | 429-437 | T23 | patients | PatientOrDisabledGroup | 429 | 437 | A21 | Accordingly, tissue-type plasminogen activator (t-PA) is frequently administered to patients with recurrent infarction presenting more than four days from previous treatment with streptokinase. | 339-551 | 339 | 551 | Accordingly, @SUBJECT$ (t-PA) is frequently @PREDICAT$ to @OBJECT$ with recurrent infarction presenting more than four days from previous treatment with streptokinase. |
Fact | preserve | 1069-1072 | 1069-1072 | T63 | for | TREATS | 1,069 | 1,072 | preserve | 1049-1068 | 1061-1068 | T57 | acupuncture therapy | TherapeuticOrPreventiveProcedure | 1,049 | 1,068 | preserve | 1086-1094 | 1086-1094 | T59 | patients | PatientOrDisabledGroup | 1,086 | 1,094 | A1 | This result did not postulate the previous study that acupuncture therapy for stroke patients should depend on needle manual and "de qi" response. | 988-1147 | 988 | 1,147 | This result did not postulate the previous study that @SUBJECT$ @PREDICAT$ stroke @OBJECT$ should depend on needle manual and "de qi" response. |
Fact | preserve | 1069-1072 | 1069-1072 | T63 | for | TREATS | 1,069 | 1,072 | preserve | 1049-1068 | 1061-1068 | T57 | acupuncture therapy | TherapeuticOrPreventiveProcedure | 1,049 | 1,068 | preserve | 1073-1079 | 1073-1079 | T58 | stroke | DiseaseOrSyndrome | 1,073 | 1,079 | A2 | This result did not postulate the previous study that acupuncture therapy for stroke patients should depend on needle manual and "de qi" response. | 988-1147 | 988 | 1,147 | This result did not postulate the previous study that @SUBJECT$ @PREDICAT$ @OBJECT$ patients should depend on needle manual and "de qi" response. |
Fact | preserve | 1343-1358 | 1350-1358 | T77 | stroke patients | PROCESS_OF | 1,343 | 1,358 | preserve | 1343-1349 | 1343-1349 | T74 | stroke | DiseaseOrSyndrome | 1,343 | 1,349 | preserve | 1350-1358 | 1350-1358 | T75 | patients | PatientOrDisabledGroup | 1,350 | 1,358 | A3 | We suggest that electrical acupuncture through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective therapy for stroke patients. | 1148-1359 | 1,148 | 1,359 | We suggest that electrical acupuncture through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective therapy for @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 252-259 | 252-259 | T20 | receive | ADMINISTERED_TO | 252 | 259 | preserve | 318-329 | 318-329 | T17 | acupuncture | TherapeuticOrPreventiveProcedure | 318 | 329 | preserve | 206-214 | 206-214 | T13 | patients | PatientOrDisabledGroup | 206 | 214 | A4 | To assess the efficacy of electrical acupuncture in the rehabilitation of patients with hemiplegia in stroke, we randomized 128 patients within 2 wk of stroke onset to receive either comprehensive rehabilitation plus electrical acupuncture (n = 59) or comprehensive rehabilitation only (n = 59). | 72-385 | 72 | 385 | To assess the efficacy of electrical acupuncture in the rehabilitation of patients with hemiplegia in stroke, we randomized 128 @OBJECT$ within 2 wk of stroke onset to @PREDICAT$ either comprehensive rehabilitation plus electrical @SUBJECT$ (n = 59) or comprehensive rehabilitation only (n = 59). |
Fact | preserve | 1073-1094 | 1086-1094 | T62 | stroke patients | PROCESS_OF | 1,073 | 1,094 | preserve | 1073-1079 | 1073-1079 | T58 | stroke | DiseaseOrSyndrome | 1,073 | 1,079 | preserve | 1086-1094 | 1086-1094 | T59 | patients | PatientOrDisabledGroup | 1,086 | 1,094 | A5 | This result did not postulate the previous study that acupuncture therapy for stroke patients should depend on needle manual and "de qi" response. | 988-1147 | 988 | 1,147 | This result did not postulate the previous study that acupuncture therapy for @SUBJECT$ @PREDICAT$ @OBJECT$ should depend on needle manual and "de qi" response. |
Fact | preserve | 717-724 | 717-724 | T53 | treated | TREATS | 717 | 724 | preserve | 747-758 | 747-758 | T40 | acupuncture | TherapeuticOrPreventiveProcedure | 747 | 758 | preserve | 708-716 | 708-716 | T38 | Patients | PatientOrDisabledGroup | 708 | 716 | A6 | Patients treated with electrical acupuncture had a shorter duration of hospital stay for rehabilitation and better neurological and functional outcomes than the control group had, with a significant difference in scores for self-care and locomotion (P = 0.02). | 708-987 | 708 | 987 | @OBJECT$ @PREDICAT$ with electrical @SUBJECT$ had a shorter duration of hospital stay for rehabilitation and better neurological and functional outcomes than the control group had, with a significant difference in scores for self-care and locomotion (P = 0.02). |
Fact | preserve | 161-165 | 161-165 | T18 | with | PROCESS_OF | 161 | 165 | preserve | 166-176 | 166-176 | T11 | hemiplegia | SignOrSymptom | 166 | 176 | preserve | 152-160 | 152-160 | T10 | patients | PatientOrDisabledGroup | 152 | 160 | A7 | To assess the efficacy of electrical acupuncture in the rehabilitation of patients with hemiplegia in stroke, we randomized 128 patients within 2 wk of stroke onset to receive either comprehensive rehabilitation plus electrical acupuncture (n = 59) or comprehensive rehabilitation only (n = 59). | 72-385 | 72 | 385 | To assess the efficacy of electrical acupuncture in the rehabilitation of @OBJECT$ @PREDICAT$ @SUBJECT$ in stroke, we randomized 128 patients within 2 wk of stroke onset to receive either comprehensive rehabilitation plus electrical acupuncture (n = 59) or comprehensive rehabilitation only (n = 59). |
Probable | preserve | 1325-1332 | 1325-1332 | T76 | therapy | TREATS | 1,325 | 1,332 | preserve | 1181-1192 | 1181-1192 | T66 | acupuncture | TherapeuticOrPreventiveProcedure | 1,181 | 1,192 | preserve | 1343-1349 | 1343-1349 | T74 | stroke | DiseaseOrSyndrome | 1,343 | 1,349 | A8 | We suggest that electrical acupuncture through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective therapy for stroke patients. | 1148-1359 | 1,148 | 1,359 | We suggest that electrical @SUBJECT$ through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective @PREDICAT$ for @OBJECT$ patients. |
Fact | preserve | 55-70 | 62-70 | T7 | stroke patients | PROCESS_OF | 55 | 70 | preserve | 55-61 | 55-61 | T5 | stroke | DiseaseOrSyndrome | 55 | 61 | preserve | 62-70 | 62-70 | T6 | patients | PatientOrDisabledGroup | 62 | 70 | A9 | Clinical trial of electrical acupuncture on hemiplegic stroke patients. | 0-71 | 0 | 71 | Clinical trial of electrical acupuncture on hemiplegic @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 177-179 | 177-179 | T19 | in | ASSOCIATED_WITH | 177 | 179 | preserve | 166-176 | 166-176 | T11 | hemiplegia | SignOrSymptom | 166 | 176 | preserve | 180-186 | 180-186 | T12 | stroke | DiseaseOrSyndrome | 180 | 186 | A10 | To assess the efficacy of electrical acupuncture in the rehabilitation of patients with hemiplegia in stroke, we randomized 128 patients within 2 wk of stroke onset to receive either comprehensive rehabilitation plus electrical acupuncture (n = 59) or comprehensive rehabilitation only (n = 59). | 72-385 | 72 | 385 | To assess the efficacy of electrical acupuncture in the rehabilitation of patients with @SUBJECT$ @PREDICAT$ @OBJECT$ , we randomized 128 patients within 2 wk of stroke onset to receive either comprehensive rehabilitation plus electrical acupuncture (n = 59) or comprehensive rehabilitation only (n = 59). |
Probable | preserve | 1325-1332 | 1325-1332 | T76 | therapy | TREATS | 1,325 | 1,332 | preserve | 1181-1192 | 1181-1192 | T66 | acupuncture | TherapeuticOrPreventiveProcedure | 1,181 | 1,192 | preserve | 1350-1358 | 1350-1358 | T75 | patients | PatientOrDisabledGroup | 1,350 | 1,358 | A11 | We suggest that electrical acupuncture through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective therapy for stroke patients. | 1148-1359 | 1,148 | 1,359 | We suggest that electrical @SUBJECT$ through adhesive surface electrodes in conjunction with current optimal rehabilitation programs is a convenient and effective @PREDICAT$ for stroke @OBJECT$ . |
Fact | preserve | 432-434 | 432-434 | T31 | by | METHOD_OF | 432 | 434 | preserve | 435-457 | 446-457 | T23 | electrical stimulation | LaboratoryProcedure | 435 | 457 | preserve | 403-414 | 403-414 | T22 | acupuncture | TherapeuticOrPreventiveProcedure | 403 | 414 | A12 | Electrical acupuncture was administered by electrical stimulation of acupuncture points through adhesive surface electrodes five times per week. | 386-542 | 386 | 542 | Electrical @OBJECT$ was administered @PREDICAT$ @SUBJECT$ of acupuncture points through adhesive surface electrodes five times per week. |
Fact | preserve | 612-637 | 627-637 | T40 | antidepressant treatments | USES | 612 | 637 | preserve | 627-637 | 627-637 | T33 | treatments | TherapeuticOrPreventiveProcedure | 627 | 637 | preserve | 612-626 | 612-626 | T32 | antidepressant | PharmacologicSubstance | 612 | 626 | A1 | The different classes of antidepressant treatments were subsequently shown to enhance serotonin neurotransmission albeit via different pre- and postsynaptic mechanisms. | 581-761 | 581 | 761 | The different classes of @OBJECT$ @PREDICAT$ @SUBJECT$ were subsequently shown to enhance serotonin neurotransmission albeit via different pre- and postsynaptic mechanisms. |
Uncommitted | preserve | 49-51 | 49-51 | T7 | in | ASSOCIATED_WITH | 49 | 51 | preserve | 0-9 | 0-9 | T1 | Serotonin | NeuroreactiveSubstanceOrBiogenicAmine | 0 | 9 | preserve | 101-116 | 107-116 | T6 | panic disorders | MentalOrBehavioralDysfunction | 101 | 116 | A2 | Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. | 0-117 | 0 | 117 | @SUBJECT$ and drug-induced therapeutic responses @PREDICAT$ major depression, obsessive-compulsive and @OBJECT$ . |
Uncommitted | preserve | 49-51 | 49-51 | T7 | in | ASSOCIATED_WITH | 49 | 51 | preserve | 0-9 | 0-9 | T1 | Serotonin | NeuroreactiveSubstanceOrBiogenicAmine | 0 | 9 | preserve | 52-68 | 58-68 | T5 | major depression | MentalOrBehavioralDysfunction | 52 | 68 | A3 | Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. | 0-117 | 0 | 117 | @SUBJECT$ and drug-induced therapeutic responses @PREDICAT$ @OBJECT$ , obsessive-compulsive and panic disorders. |
Fact | preserve | 172-174 | 172-174 | T13 | in | TREATS | 172 | 174 | preserve | 151-171 | 166-171 | T11 | antidepressant drugs | PharmacologicSubstance | 151 | 171 | preserve | 175-191 | 181-191 | T12 | major depression | MentalOrBehavioralDysfunction | 175 | 191 | A4 | The therapeutic effectiveness of antidepressant drugs in major depression was discovered by pure serendipity. | 118-233 | 118 | 233 | The therapeutic effectiveness of @SUBJECT$ @PREDICAT$ @OBJECT$ was discovered by pure serendipity. |
Fact | preserve | 1247-1250 | 1247-1250 | T65 | for | TREATS | 1,247 | 1,250 | preserve | 1226-1235 | 1226-1235 | T62 | treatment | TherapeuticOrPreventiveProcedure | 1,226 | 1,235 | preserve | 1257-1266 | 1257-1266 | T64 | disorders | DiseaseOrSyndrome | 1,257 | 1,266 | A5 | It is expected that the better understanding recently obtained of the mechanism of action of certain antidepressant drugs in obsessive-compulsive and panic disorders will also lead to more effective treatment strategies for those disorders. | 1008-1267 | 1,008 | 1,267 | It is expected that the better understanding recently obtained of the mechanism of action of certain antidepressant drugs in obsessive-compulsive and panic disorders will also lead to more effective @SUBJECT$ strategies @PREDICAT$ those @OBJECT$ . |
Fact | preserve | 736-743 | 736-743 | T37 | treated | TREATS | 736 | 743 | preserve | 749-764 | 749-764 | T35 | glucocorticoids | Hormone | 749 | 764 | preserve | 708-714 | 708-714 | T34 | asthma | DiseaseOrSyndrome | 708 | 714 | A1 | Adults with stable asthma, either untreated or treated with glucocorticoids (GCs), were enrolled. | 683-792 | 683 | 792 | Adults with stable @OBJECT$ , either untreated or @PREDICAT$ with @SUBJECT$ (GCs), were enrolled. |
Fact | preserve | 1525-1527 | 1525-1527 | T78 | in | PROCESS_OF | 1,525 | 1,527 | preserve | 1482-1490 | 1482-1490 | T74 | fibrosis | PathologicFunction | 1,482 | 1,490 | preserve | 1528-1536 | 1528-1536 | T75 | patients | PatientOrDisabledGroup | 1,528 | 1,536 | A2 | This observation has important implications, since an excess of TIMP-1 could lead to airway fibrosis, a hallmark of airway remodelling in patients with chronic asthma. | 1384-1564 | 1,384 | 1,564 | This observation has important implications, since an excess of TIMP-1 could lead to airway @SUBJECT$ , a hallmark of airway remodelling @PREDICAT$ @OBJECT$ with chronic asthma. |
Uncommitted | preserve | 521-523 | 521-523 | T24 | in | PROCESS_OF | 521 | 523 | preserve | 448-457 | 448-457 | T18 | imbalance | SignOrSymptom | 448 | 457 | preserve | 535-543 | 535-543 | T21 | patients | PatientOrDisabledGroup | 535 | 543 | A3 | The accumulation in the submucosa of fibrous proteins that are substrates of matrix metalloproteinases (MMP), and the demonstration of increased levels of MMP-9 in bronchoalveolar lavage fluid, prompted us to determine whether there was an imbalance between MMPs and tissue inhibitors of metalloproteinase (TIMP) in such patients. | 190-544 | 190 | 544 | The accumulation in the submucosa of fibrous proteins that are substrates of matrix metalloproteinases (MMP), and the demonstration of increased levels of MMP-9 in bronchoalveolar lavage fluid, prompted us to determine whether there was an @SUBJECT$ between MMPs and tissue inhibitors of metalloproteinase (TIMP) @PREDICAT$ such @OBJECT$ . |
Fact | preserve | 736-743 | 736-743 | T37 | treated | TREATS | 736 | 743 | preserve | 749-764 | 749-764 | T35 | glucocorticoids | Hormone | 749 | 764 | preserve | 683-689 | 683-689 | T33 | Adults | AgeGroup | 683 | 689 | A4 | Adults with stable asthma, either untreated or treated with glucocorticoids (GCs), were enrolled. | 683-792 | 683 | 792 | @OBJECT$ with stable asthma, either untreated or @PREDICAT$ with @SUBJECT$ (GCs), were enrolled. |
Fact | preserve | 690-694 | 690-694 | T36 | with | PROCESS_OF | 690 | 694 | preserve | 708-714 | 708-714 | T34 | asthma | DiseaseOrSyndrome | 708 | 714 | preserve | 683-689 | 683-689 | T33 | Adults | AgeGroup | 683 | 689 | A5 | Adults with stable asthma, either untreated or treated with glucocorticoids (GCs), were enrolled. | 683-792 | 683 | 792 | @OBJECT$ @PREDICAT$ stable @SUBJECT$ , either untreated or treated with glucocorticoids (GCs), were enrolled. |
Fact | preserve | 253-263 | 253-263 | T22 | substrates | INTERACTS_WITH | 253 | 263 | preserve | 227-243 | 235-243 | T12 | fibrous proteins | AminoAcidPeptideOrProtein | 227 | 243 | preserve | 273-298 | 280-298 | T13 | matrix metalloproteinases | AminoAcidPeptideOrProtein | 273 | 298 | A6 | The accumulation in the submucosa of fibrous proteins that are substrates of matrix metalloproteinases (MMP), and the demonstration of increased levels of MMP-9 in bronchoalveolar lavage fluid, prompted us to determine whether there was an imbalance between MMPs and tissue inhibitors of metalloproteinase (TIMP) in such patients. | 190-544 | 190 | 544 | The accumulation in the submucosa of @SUBJECT$ that are @PREDICAT$ of @OBJECT$ (MMP), and the demonstration of increased levels of MMP-9 in bronchoalveolar lavage fluid, prompted us to determine whether there was an imbalance between MMPs and tissue inhibitors of metalloproteinase (TIMP) in such patients. |
Fact | preserve | 169-173 | 169-173 | T11 | with | PROCESS_OF | 169 | 173 | preserve | 182-188 | 182-188 | T10 | asthma | DiseaseOrSyndrome | 182 | 188 | preserve | 160-168 | 160-168 | T8 | patients | PatientOrDisabledGroup | 160 | 168 | A7 | Airway remodeling is a well-recognized feature in patients with chronic asthma. | 110-189 | 110 | 189 | Airway remodeling is a well-recognized feature in @OBJECT$ @PREDICAT$ chronic @SUBJECT$ . |
Fact | preserve | 363-365 | 363-365 | T23 | in | LOCATION_OF | 363 | 365 | preserve | 366-394 | 389-394 | T17 | bronchoalveolar lavage fluid | BodySubstance | 366 | 394 | preserve | 357-362 | 357-362 | T16 | MMP-9 | AminoAcidPeptideOrProtein | 357 | 362 | A8 | The accumulation in the submucosa of fibrous proteins that are substrates of matrix metalloproteinases (MMP), and the demonstration of increased levels of MMP-9 in bronchoalveolar lavage fluid, prompted us to determine whether there was an imbalance between MMPs and tissue inhibitors of metalloproteinase (TIMP) in such patients. | 190-544 | 190 | 544 | The accumulation in the submucosa of fibrous proteins that are substrates of matrix metalloproteinases (MMP), and the demonstration of increased levels of @OBJECT$ @PREDICAT$ @SUBJECT$ , prompted us to determine whether there was an imbalance between MMPs and tissue inhibitors of metalloproteinase (TIMP) in such patients. |
Fact | preserve | 1537-1541 | 1537-1541 | T79 | with | PROCESS_OF | 1,537 | 1,541 | preserve | 1557-1563 | 1557-1563 | T77 | asthma | DiseaseOrSyndrome | 1,557 | 1,563 | preserve | 1528-1536 | 1528-1536 | T75 | patients | PatientOrDisabledGroup | 1,528 | 1,536 | A9 | This observation has important implications, since an excess of TIMP-1 could lead to airway fibrosis, a hallmark of airway remodelling in patients with chronic asthma. | 1384-1564 | 1,384 | 1,564 | This observation has important implications, since an excess of TIMP-1 could lead to airway fibrosis, a hallmark of airway remodelling in @OBJECT$ @PREDICAT$ chronic @SUBJECT$ . |
Fact | preserve | 1996-2005 | 1996-2005 | T116 | treatment | TREATS | 1,996 | 2,005 | preserve | 2013-2040 | 2031-2040 | T112 | monoamine oxidase inhibitor | PharmacologicSubstance | 2,013 | 2,040 | preserve | 2069-2094 | 2086-2094 | T114 | major depressive disorder | MentalOrBehavioralDysfunction | 2,069 | 2,094 | A1 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major depressive disorder and atypical features. | 1900-2117 | 1,900 | 2,117 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase @PREDICAT$ with a @SUBJECT$ for outpatients with @OBJECT$ and atypical features. |
Fact | preserve | 1514-1518 | 1514-1518 | T94 | than | compared_with | 1,514 | 1,518 | preserve | 1434-1444 | 1434-1444 | T80 | Phenelzine | OrganicChemical | 1,434 | 1,444 | preserve | 1519-1526 | 1519-1526 | T84 | placebo | MedicalDevice | 1,519 | 1,526 | A3 | Phenelzine and cognitive therapy also reduced symptoms significantly more than placebo according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. | 1434-1727 | 1,434 | 1,727 | @SUBJECT$ and cognitive therapy also reduced symptoms significantly more @PREDICAT$ @OBJECT$ according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. |
Fact | preserve | 1996-2005 | 1996-2005 | T116 | treatment | TREATS | 1,996 | 2,005 | preserve | 2013-2040 | 2031-2040 | T112 | monoamine oxidase inhibitor | PharmacologicSubstance | 2,013 | 2,040 | preserve | 2052-2063 | 2052-2063 | T113 | outpatients | PatientOrDisabledGroup | 2,052 | 2,063 | A4 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major depressive disorder and atypical features. | 1900-2117 | 1,900 | 2,117 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase @PREDICAT$ with a @SUBJECT$ for @OBJECT$ with major depressive disorder and atypical features. |
Fact | preserve | 501-509 | 501-509 | T30 | compared | compared_with | 501 | 509 | preserve | 483-500 | 493-500 | T28 | cognitive therapy | TherapeuticOrPreventiveProcedure | 483 | 500 | preserve | 517-550 | 541-550 | T29 | monoamine oxidase inhibitor | PharmacologicSubstance | 517 | 550 | A5 | There are no prospective, randomized, controlled trials, to our knowledge, of psychotherapy for atypical depression or of cognitive therapy compared with a monoamine oxidase inhibitor. | 349-551 | 349 | 551 | There are no prospective, randomized, controlled trials, to our knowledge, of psychotherapy for atypical depression or of @SUBJECT$ @PREDICAT$ with a @OBJECT$ . |
Fact | preserve | 722-726 | 722-726 | T55 | with | PROCESS_OF | 722 | 726 | preserve | 737-762 | 754-762 | T45 | major depressive disorder | MentalOrBehavioralDysfunction | 737 | 762 | preserve | 710-721 | 710-721 | T43 | Outpatients | PatientOrDisabledGroup | 710 | 721 | A6 | METHODS: Outpatients with DSM-III-R major depressive disorder and atypical features (N = 108) were treated in a 10-week, double-blind, randomized, controlled trial comparing acute-phase cognitive therapy or clinical management plus either phenelzine sulfate or placebo. | 701-988 | 701 | 988 | METHODS: @OBJECT$ @PREDICAT$ DSM-III-R @SUBJECT$ and atypical features (N = 108) were treated in a 10-week, double-blind, randomized, controlled trial comparing acute-phase cognitive therapy or clinical management plus either phenelzine sulfate or placebo. |
Fact | preserve | 685-688 | 685-688 | T41 | for | TREATS | 685 | 688 | preserve | 671-684 | 671-684 | T39 | psychotherapy | TherapeuticOrPreventiveProcedure | 671 | 684 | preserve | 689-699 | 689-699 | T40 | depression | MentalOrBehavioralDysfunction | 689 | 699 | A7 | Since there is only 1 placebo-controlled trial of cognitive therapy, this trial fills a gap in the literature on psychotherapy for depression. | 552-700 | 552 | 700 | Since there is only 1 placebo-controlled trial of cognitive therapy, this trial fills a gap in the literature on @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 0-9 | 0-9 | T8 | Treatment | TREATS | 0 | 9 | preserve | 59-69 | 59-69 | T4 | phenelzine | OrganicChemical | 59 | 69 | preserve | 13-32 | 22-32 | T2 | atypical depression | MentalOrBehavioralDysfunction | 13 | 32 | A8 | Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. | 0-118 | 0 | 118 | @PREDICAT$ of @OBJECT$ with cognitive therapy or @SUBJECT$ : a double-blind, placebo-controlled trial. |
Fact | preserve | 2064-2068 | 2064-2068 | T117 | with | PROCESS_OF | 2,064 | 2,068 | preserve | 2069-2094 | 2086-2094 | T114 | major depressive disorder | MentalOrBehavioralDysfunction | 2,069 | 2,094 | preserve | 2052-2063 | 2052-2063 | T113 | outpatients | PatientOrDisabledGroup | 2,052 | 2,063 | A9 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for outpatients with major depressive disorder and atypical features. | 1900-2117 | 1,900 | 2,117 | CONCLUSIONS: Cognitive therapy may offer an effective alternative to standard acute-phase treatment with a monoamine oxidase inhibitor for @OBJECT$ @PREDICAT$ @SUBJECT$ and atypical features. |
Fact | preserve | 0-9 | 0-9 | T8 | Treatment | TREATS | 0 | 9 | preserve | 38-55 | 48-55 | T3 | cognitive therapy | TherapeuticOrPreventiveProcedure | 38 | 55 | preserve | 13-32 | 22-32 | T2 | atypical depression | MentalOrBehavioralDysfunction | 13 | 32 | A10 | Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. | 0-118 | 0 | 118 | @PREDICAT$ of @OBJECT$ with @SUBJECT$ or phenelzine: a double-blind, placebo-controlled trial. |
Fact | preserve | 140-144 | 140-144 | T16 | with | PROCESS_OF | 140 | 144 | preserve | 145-164 | 154-164 | T11 | atypical depression | MentalOrBehavioralDysfunction | 145 | 164 | preserve | 131-139 | 131-139 | T10 | Patients | PatientOrDisabledGroup | 131 | 139 | A11 | BACKGROUND: Patients with atypical depression are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepressants. | 119-264 | 119 | 264 | BACKGROUND: @OBJECT$ @PREDICAT$ @SUBJECT$ are more likely to respond to monoamine oxidase inhibitors than to tricyclic antidepressants. |
Fact | preserve | 1514-1518 | 1514-1518 | T95 | than | higher_than | 1,514 | 1,518 | preserve | 1434-1444 | 1434-1444 | T80 | Phenelzine | OrganicChemical | 1,434 | 1,444 | preserve | 1519-1526 | 1519-1526 | T84 | placebo | MedicalDevice | 1,519 | 1,526 | A12 | Phenelzine and cognitive therapy also reduced symptoms significantly more than placebo according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. | 1434-1727 | 1,434 | 1,727 | @SUBJECT$ and cognitive therapy also reduced symptoms significantly more @PREDICAT$ @OBJECT$ according to contrasts after a repeated-measures analysis of covariance and random regression with the use of the blind evaluator's final Hamilton Rating Scale for Depression score. |
Fact | preserve | 453-456 | 453-456 | T31 | for | TREATS | 453 | 456 | preserve | 433-446 | 433-446 | T26 | psychotherapy | TherapeuticOrPreventiveProcedure | 433 | 446 | preserve | 457-476 | 466-476 | T27 | atypical depression | MentalOrBehavioralDysfunction | 457 | 476 | A13 | There are no prospective, randomized, controlled trials, to our knowledge, of psychotherapy for atypical depression or of cognitive therapy compared with a monoamine oxidase inhibitor. | 349-551 | 349 | 551 | There are no prospective, randomized, controlled trials, to our knowledge, of @SUBJECT$ @PREDICAT$ @OBJECT$ or of cognitive therapy compared with a monoamine oxidase inhibitor. |
Probable | preserve | 867-874 | 867-874 | T67 | therapy | TREATS | 867 | 874 | preserve | 846-856 | 846-856 | T64 | salmeterol | OrganicChemical | 846 | 856 | preserve | 860-866 | 860-866 | T65 | asthma | DiseaseOrSyndrome | 860 | 866 | A1 | The above results indicate the great efficacy of salmeterol in asthma therapy. | 791-875 | 791 | 875 | The above results indicate the great efficacy of @SUBJECT$ in @OBJECT$ @PREDICAT$ . |
Fact | preserve | 165-172 | 165-172 | T19 | therapy | TREATS | 165 | 172 | preserve | 138-148 | 138-148 | T16 | salmeterol | OrganicChemical | 138 | 148 | preserve | 152-158 | 152-158 | T17 | asthma | DiseaseOrSyndrome | 152 | 158 | A2 | The purpose of the study was to evaluate the efficacy of salmeterol in asthma therapy. | 81-173 | 81 | 173 | The purpose of the study was to evaluate the efficacy of @SUBJECT$ in @OBJECT$ @PREDICAT$ . |
Fact | preserve | 215-239 | 231-239 | T26 | allergic asthma patients | PROCESS_OF | 215 | 239 | preserve | 215-230 | 224-230 | T22 | allergic asthma | DiseaseOrSyndrome | 215 | 230 | preserve | 231-239 | 231-239 | T23 | patients | PatientOrDisabledGroup | 231 | 239 | A3 | The study was performed on a group of 16 allergic asthma patients sensitive to house dust mite allergens. | 174-285 | 174 | 285 | The study was performed on a group of 16 @SUBJECT$ @PREDICAT$ @OBJECT$ sensitive to house dust mite allergens. |
Fact | preserve | 51-53 | 51-53 | T10 | in | TREATS | 51 | 53 | preserve | 43-50 | 43-50 | T4 | therapy | TherapeuticOrPreventiveProcedure | 43 | 50 | preserve | 70-78 | 70-78 | T6 | patients | PatientOrDisabledGroup | 70 | 78 | A5 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week salmeterol @SUBJECT$ @PREDICAT$ allergic asthma @OBJECT$ ]. |
Fact | preserve | 51-53 | 51-53 | T10 | in | TREATS | 51 | 53 | preserve | 43-50 | 43-50 | T4 | therapy | TherapeuticOrPreventiveProcedure | 43 | 50 | preserve | 54-69 | 63-69 | T5 | allergic asthma | DiseaseOrSyndrome | 54 | 69 | A6 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week salmeterol @SUBJECT$ @PREDICAT$ @OBJECT$ patients]. |
Fact | preserve | 32-50 | 43-50 | T12 | salmeterol therapy | TREATS | 32 | 50 | preserve | 32-42 | 32-42 | T3 | salmeterol | OrganicChemical | 32 | 42 | preserve | 70-78 | 70-78 | T6 | patients | PatientOrDisabledGroup | 70 | 78 | A7 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week @SUBJECT$ @PREDICAT$ in allergic asthma @OBJECT$ ]. |
Fact | preserve | 32-50 | 43-50 | T8 | salmeterol therapy | USES | 32 | 50 | preserve | 43-50 | 43-50 | T4 | therapy | TherapeuticOrPreventiveProcedure | 43 | 50 | preserve | 32-42 | 32-42 | T3 | salmeterol | OrganicChemical | 32 | 42 | A8 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week @OBJECT$ @PREDICAT$ @SUBJECT$ in allergic asthma patients]. |
Fact | preserve | 565-588 | 578-588 | T48 | clinic spirometry | USES | 565 | 588 | preserve | 578-588 | 578-588 | T47 | spirometry | DiagnosticProcedure | 578 | 588 | preserve | 565-571 | 565-571 | T46 | clinic | HealthCareRelatedOrganization | 565 | 571 | A9 | On the visit to the clinic spirometry was performed. | 545-603 | 545 | 603 | On the visit to the @OBJECT$ @PREDICAT$ @SUBJECT$ was performed. |
Fact | preserve | 32-50 | 43-50 | T7 | salmeterol therapy | ISA | 32 | 50 | preserve | 32-42 | 32-42 | T3 | salmeterol | OrganicChemical | 32 | 42 | preserve | 43-50 | 43-50 | T4 | therapy | TherapeuticOrPreventiveProcedure | 43 | 50 | A10 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week @SUBJECT$ @PREDICAT$ @OBJECT$ in allergic asthma patients]. |
Fact | preserve | 54-78 | 70-78 | T9 | allergic asthma patients | PROCESS_OF | 54 | 78 | preserve | 54-69 | 63-69 | T5 | allergic asthma | DiseaseOrSyndrome | 54 | 69 | preserve | 70-78 | 70-78 | T6 | patients | PatientOrDisabledGroup | 70 | 78 | A11 | [Clinical evaluation of 12 week salmeterol therapy in allergic asthma patients]. | 0-80 | 0 | 80 | [Clinical evaluation of 12 week salmeterol therapy in @SUBJECT$ @PREDICAT$ @OBJECT$ ]. |
Fact | preserve | 332-339 | 332-339 | T35 | treated | TREATS | 332 | 339 | preserve | 345-355 | 345-355 | T30 | salmeterol | OrganicChemical | 345 | 355 | preserve | 312-320 | 312-320 | T29 | patients | PatientOrDisabledGroup | 312 | 320 | A12 | After a run-in period the patients were treated with salmeterol, 2 x 50 micrograms, for a period of 12 weeks. | 286-401 | 286 | 401 | After a run-in period the @OBJECT$ were @PREDICAT$ with @SUBJECT$ , 2 x 50 micrograms, for a period of 12 weeks. |
Fact | preserve | 834-841 | 834-841 | T45 | treated | TREATS | 834 | 841 | preserve | 847-860 | 847-860 | T43 | streptokinase | AminoAcidPeptideOrProtein | 847 | 860 | preserve | 825-833 | 825-833 | T42 | patients | PatientOrDisabledGroup | 825 | 833 | A1 | The cumulative 1-, 5- and 10-year survival rates were 91%, 81% and 69% in patients treated with streptokinase and 84%, 71% and 59% in the control group, respectively (P=0.02). | 745-932 | 745 | 932 | The cumulative 1-, 5- and 10-year survival rates were 91%, 81% and 69% in @OBJECT$ @PREDICAT$ with @SUBJECT$ and 84%, 71% and 59% in the control group, respectively (P=0.02). |
Probable | preserve | 1156-1161 | 1156-1161 | T59 | after | PRECEDES | 1,156 | 1,161 | preserve | 1162-1182 | 1175-1182 | T58 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 1,162 | 1,182 | preserve | 1079-1093 | 1086-1093 | T54 | bypass surgery | TherapeuticOrPreventiveProcedure | 1,079 | 1,093 | A3 | Coronary bypass surgery and coronary angioplasty were more frequently performed after thrombolytic therapy. | 1070-1183 | 1,070 | 1,183 | Coronary @OBJECT$ and coronary angioplasty were more frequently performed @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 70-72 | 70-72 | T7 | in | TREATS | 70 | 72 | preserve | 49-69 | 62-69 | T5 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 49 | 69 | preserve | 79-100 | 90-100 | T6 | myocardial infarction | DiseaseOrSyndrome | 79 | 100 | A5 | Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction. | 0-101 | 0 | 101 | Sustained benefit at 10-14 years follow-up after @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 633-655 | 646-655 | T38 | thrombolytic treatment | USES | 633 | 655 | preserve | 646-655 | 646-655 | T34 | treatment | TherapeuticOrPreventiveProcedure | 646 | 655 | preserve | 633-645 | 633-645 | T33 | thrombolytic | PharmacologicSubstance | 633 | 645 | A6 | At follow-up, 158 patients (59%) of the 269 patients allocated to thrombolytic treatment and only 129 patients (49%) of the 264 conventionally treated patients were alive. | 561-744 | 561 | 744 | At follow-up, 158 patients (59%) of the 269 patients allocated to @OBJECT$ @PREDICAT$ @SUBJECT$ and only 129 patients (49%) of the 264 conventionally treated patients were alive. |
Probable | preserve | 1156-1161 | 1156-1161 | T59 | after | PRECEDES | 1,156 | 1,161 | preserve | 1162-1182 | 1175-1182 | T58 | thrombolytic therapy | TherapeuticOrPreventiveProcedure | 1,162 | 1,182 | preserve | 1098-1118 | 1107-1118 | T55 | coronary angioplasty | TherapeuticOrPreventiveProcedure | 1,098 | 1,118 | A7 | Coronary bypass surgery and coronary angioplasty were more frequently performed after thrombolytic therapy. | 1070-1183 | 1,070 | 1,183 | Coronary bypass surgery and @OBJECT$ were more frequently performed @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1497-1499 | 1497-1499 | T92 | in | TREATS | 1,497 | 1,499 | preserve | 1442-1455 | 1442-1455 | T82 | Beta-blockers | PharmacologicSubstance | 1,442 | 1,455 | preserve | 1500-1508 | 1500-1508 | T84 | patients | PatientOrDisabledGroup | 1,500 | 1,508 | A1 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | @SUBJECT$ seem to be safe and well tolerated @PREDICAT$ @OBJECT$ with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. |
Fact | preserve | 1688-1692 | 1688-1692 | T103 | with | PROCESS_OF | 1,688 | 1,692 | preserve | 1693-1699 | 1693-1699 | T101 | asthma | DiseaseOrSyndrome | 1,693 | 1,699 | preserve | 1679-1687 | 1679-1687 | T100 | patients | PatientOrDisabledGroup | 1,679 | 1,687 | A2 | Beta-blockers should not be used in patients with asthma. | 1643-1700 | 1,643 | 1,700 | Beta-blockers should not be used in @OBJECT$ @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1351-1353 | 1351-1353 | T80 | in | PROCESS_OF | 1,351 | 1,353 | preserve | 1321-1326 | 1321-1326 | T71 | death | OrganismFunction | 1,321 | 1,326 | preserve | 1382-1390 | 1382-1390 | T76 | patients | PatientOrDisabledGroup | 1,382 | 1,390 | A3 | Calcium channel antagonists may have some effect in retarding progression of diabetic nephropathy although a recent trial found a higher incidence of death as a secondary endpoint in hypertensive diabetic patients who were treated with calcium channel antagonists. | 1158-1441 | 1,158 | 1,441 | Calcium channel antagonists may have some effect in retarding progression of diabetic nephropathy although a recent trial found a higher incidence of @SUBJECT$ as a secondary endpoint @PREDICAT$ hypertensive diabetic @OBJECT$ who were treated with calcium channel antagonists. |
Counterfact | preserve | 1676-1678 | 1676-1678 | T102 | in | TREATS | 1,676 | 1,678 | preserve | 1643-1656 | 1643-1656 | T98 | Beta-blockers | PharmacologicSubstance | 1,643 | 1,656 | preserve | 1679-1687 | 1679-1687 | T100 | patients | PatientOrDisabledGroup | 1,679 | 1,687 | A4 | Beta-blockers should not be used in patients with asthma. | 1643-1700 | 1,643 | 1,700 | @SUBJECT$ should not be used @PREDICAT$ @OBJECT$ with asthma. |
Fact | preserve | 1032-1036 | 1032-1036 | T53 | have | PROCESS_OF | 1,032 | 1,036 | preserve | 1043-1059 | 1043-1059 | T49 | microalbuminuria | DiseaseOrSyndrome | 1,043 | 1,059 | preserve | 999-1007 | 999-1007 | T47 | patients | PatientOrDisabledGroup | 999 | 1,007 | A5 | In patients with diabetes, ACE inhibitors are effective first-line agents in type 1 and type 2 diabetic patients who are hypertensive or have microalbuminuria. | 889-1060 | 889 | 1,060 | In patients with diabetes, ACE inhibitors are effective first-line agents in type 1 and type 2 diabetic @OBJECT$ who are hypertensive or @PREDICAT$ @SUBJECT$ . |
Fact | preserve | 1962-1967 | 1962-1967 | T132 | raise | AUGMENTS | 1,962 | 1,967 | preserve | 1928-1937 | 1928-1937 | T122 | piroxicam | OrganicChemical | 1,928 | 1,937 | preserve | 1968-1987 | 1979-1987 | T124 | mean blood pressure | Finding | 1,968 | 1,987 | A6 | NSAIDs, particularly piroxicam and indomethacin, raise mean blood pressure by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. | 1907-2131 | 1,907 | 2,131 | NSAIDs, particularly @SUBJECT$ and indomethacin, @PREDICAT$ @OBJECT$ by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. |
Fact | preserve | 1795-1797 | 1795-1797 | T116 | in | PROCESS_OF | 1,795 | 1,797 | preserve | 1782-1794 | 1782-1794 | T110 | hypertension | DiseaseOrSyndrome | 1,782 | 1,794 | preserve | 1798-1806 | 1798-1806 | T111 | patients | PatientOrDisabledGroup | 1,798 | 1,806 | A7 | Dihydropyridine calcium channel antagonists are the preferred treatment of hypertension in patients with Raynaud's but should be avoided in patients with severe gastroesophageal reflux disease. | 1701-1906 | 1,701 | 1,906 | Dihydropyridine calcium channel antagonists are the preferred treatment of @SUBJECT$ @PREDICAT$ @OBJECT$ with Raynaud's but should be avoided in patients with severe gastroesophageal reflux disease. |
Probable | preserve | 1094-1096 | 1094-1096 | T59 | in | TREATS | 1,094 | 1,096 | preserve | 1061-1075 | 1065-1075 | T55 | ACE inhibitors | PharmacologicSubstance | 1,061 | 1,075 | preserve | 1097-1105 | 1097-1105 | T56 | patients | PatientOrDisabledGroup | 1,097 | 1,105 | A8 | ACE inhibitors may be beneficial in patients with nondiabetic renal insufficiency as well. | 1061-1157 | 1,061 | 1,157 | @SUBJECT$ may be beneficial @PREDICAT$ @OBJECT$ with nondiabetic renal insufficiency as well. |
Fact | preserve | 1582-1586 | 1582-1586 | T94 | with | PROCESS_OF | 1,582 | 1,586 | preserve | 1587-1596 | 1592-1596 | T88 | rest pain | SignOrSymptom | 1,587 | 1,596 | preserve | 1573-1581 | 1573-1581 | T87 | patients | PatientOrDisabledGroup | 1,573 | 1,581 | A9 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although @OBJECT$ @PREDICAT$ @SUBJECT$ or limb ischemia have not been studied. |
Fact | preserve | 901-905 | 901-905 | T50 | with | PROCESS_OF | 901 | 905 | preserve | 906-914 | 906-914 | T38 | diabetes | DiseaseOrSyndrome | 906 | 914 | preserve | 892-900 | 892-900 | T37 | patients | PatientOrDisabledGroup | 892 | 900 | A10 | In patients with diabetes, ACE inhibitors are effective first-line agents in type 1 and type 2 diabetic patients who are hypertensive or have microalbuminuria. | 889-1060 | 889 | 1,060 | In @OBJECT$ @PREDICAT$ @SUBJECT$ , ACE inhibitors are effective first-line agents in type 1 and type 2 diabetic patients who are hypertensive or have microalbuminuria. |
Probable | preserve | 1094-1096 | 1094-1096 | T59 | in | TREATS | 1,094 | 1,096 | preserve | 1061-1075 | 1065-1075 | T55 | ACE inhibitors | PharmacologicSubstance | 1,061 | 1,075 | preserve | 1129-1148 | 1135-1148 | T57 | renal insufficiency | DiseaseOrSyndrome | 1,129 | 1,148 | A11 | ACE inhibitors may be beneficial in patients with nondiabetic renal insufficiency as well. | 1061-1157 | 1,061 | 1,157 | @SUBJECT$ may be beneficial @PREDICAT$ patients with nondiabetic @OBJECT$ as well. |
Fact | preserve | 1582-1586 | 1582-1586 | T94 | with | PROCESS_OF | 1,582 | 1,586 | preserve | 1605-1613 | 1605-1613 | T90 | ischemia | DiseaseOrSyndrome | 1,605 | 1,613 | preserve | 1573-1581 | 1573-1581 | T87 | patients | PatientOrDisabledGroup | 1,573 | 1,581 | A12 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although @OBJECT$ @PREDICAT$ rest pain or limb @SUBJECT$ have not been studied. |
Fact | preserve | 1962-1967 | 1962-1967 | T132 | raise | AUGMENTS | 1,962 | 1,967 | preserve | 1907-1913 | 1907-1913 | T121 | NSAIDs | PharmacologicSubstance | 1,907 | 1,913 | preserve | 1968-1987 | 1979-1987 | T124 | mean blood pressure | Finding | 1,968 | 1,987 | A14 | NSAIDs, particularly piroxicam and indomethacin, raise mean blood pressure by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. | 1907-2131 | 1,907 | 2,131 | @SUBJECT$ , particularly piroxicam and indomethacin, @PREDICAT$ @OBJECT$ by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. |
Fact | preserve | 990-1007 | 999-1007 | T52 | diabetic patients | PROCESS_OF | 990 | 1,007 | preserve | 990-998 | 990-998 | T46 | diabetic | Finding | 990 | 998 | preserve | 999-1007 | 999-1007 | T47 | patients | PatientOrDisabledGroup | 999 | 1,007 | A15 | In patients with diabetes, ACE inhibitors are effective first-line agents in type 1 and type 2 diabetic patients who are hypertensive or have microalbuminuria. | 889-1060 | 889 | 1,060 | In patients with diabetes, ACE inhibitors are effective first-line agents in type 1 and type 2 @SUBJECT$ @PREDICAT$ @OBJECT$ who are hypertensive or have microalbuminuria. |
Probable | preserve | 2151-2157 | 2151-2157 | T141 | induce | CAUSES | 2,151 | 2,157 | preserve | 2132-2146 | 2145-2146 | T136 | Cyclosporine A | AminoAcidPeptideOrProtein | 2,132 | 2,146 | preserve | 2158-2170 | 2158-2170 | T137 | hypertension | DiseaseOrSyndrome | 2,158 | 2,170 | A16 | Cyclosporine A can induce hypertension by its vasoconstrictive effects, particularly on the kidney. | 2132-2237 | 2,132 | 2,237 | @SUBJECT$ can @PREDICAT$ @OBJECT$ by its vasoconstrictive effects, particularly on the kidney. |
Fact | preserve | 781-790 | 781-790 | T33 | treatment | TREATS | 781 | 790 | preserve | 724-733 | 724-733 | T27 | diuretics | PharmacologicSubstance | 724 | 733 | preserve | 800-826 | 814-826 | T32 | uncomplicated hypertension | DiseaseOrSyndrome | 800 | 826 | A18 | In the absence of contraindications, beta-blockers and diuretics are still recommended as first-line agents for treatment of uncomplicated hypertension. | 663-827 | 663 | 827 | In the absence of contraindications, beta-blockers and @SUBJECT$ are still recommended as first-line agents for @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 1962-1967 | 1962-1967 | T132 | raise | AUGMENTS | 1,962 | 1,967 | preserve | 1948-1960 | 1948-1960 | T123 | indomethacin | OrganicChemical | 1,948 | 1,960 | preserve | 1968-1987 | 1979-1987 | T124 | mean blood pressure | Finding | 1,968 | 1,987 | A19 | NSAIDs, particularly piroxicam and indomethacin, raise mean blood pressure by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. | 1907-2131 | 1,907 | 2,131 | NSAIDs, particularly piroxicam and @SUBJECT$ , @PREDICAT$ @OBJECT$ by approximately 5 mm Hg, enough to consider a change of either NSAID or antihypertensive to one that is not as affected by NSAIDs. |
Counterfact | preserve | 1676-1678 | 1676-1678 | T102 | in | TREATS | 1,676 | 1,678 | preserve | 1643-1656 | 1643-1656 | T98 | Beta-blockers | PharmacologicSubstance | 1,643 | 1,656 | preserve | 1693-1699 | 1693-1699 | T101 | asthma | DiseaseOrSyndrome | 1,693 | 1,699 | A20 | Beta-blockers should not be used in patients with asthma. | 1643-1700 | 1,643 | 1,700 | @SUBJECT$ should not be used @PREDICAT$ patients with @OBJECT$ . |
Fact | preserve | 1497-1499 | 1497-1499 | T92 | in | TREATS | 1,497 | 1,499 | preserve | 1442-1455 | 1442-1455 | T82 | Beta-blockers | PharmacologicSubstance | 1,442 | 1,455 | preserve | 1531-1562 | 1550-1562 | T86 | intermittent claudication | DiseaseOrSyndrome | 1,531 | 1,562 | A21 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | @SUBJECT$ seem to be safe and well tolerated @PREDICAT$ patients with mild to moderate @OBJECT$ , although patients with rest pain or limb ischemia have not been studied. |
Fact | preserve | 1367-1390 | 1382-1390 | T79 | diabetic patients | PROCESS_OF | 1,367 | 1,390 | preserve | 1367-1375 | 1367-1375 | T75 | diabetic | Finding | 1,367 | 1,375 | preserve | 1382-1390 | 1382-1390 | T76 | patients | PatientOrDisabledGroup | 1,382 | 1,390 | A22 | Calcium channel antagonists may have some effect in retarding progression of diabetic nephropathy although a recent trial found a higher incidence of death as a secondary endpoint in hypertensive diabetic patients who were treated with calcium channel antagonists. | 1158-1441 | 1,158 | 1,441 | Calcium channel antagonists may have some effect in retarding progression of diabetic nephropathy although a recent trial found a higher incidence of death as a secondary endpoint in hypertensive @SUBJECT$ @PREDICAT$ @OBJECT$ who were treated with calcium channel antagonists. |
Fact | preserve | 1856-1860 | 1856-1860 | T119 | with | PROCESS_OF | 1,856 | 1,860 | preserve | 1874-1905 | 1898-1905 | T115 | gastroesophageal reflux disease | DiseaseOrSyndrome | 1,874 | 1,905 | preserve | 1847-1855 | 1847-1855 | T113 | patients | PatientOrDisabledGroup | 1,847 | 1,855 | A25 | Dihydropyridine calcium channel antagonists are the preferred treatment of hypertension in patients with Raynaud's but should be avoided in patients with severe gastroesophageal reflux disease. | 1701-1906 | 1,701 | 1,906 | Dihydropyridine calcium channel antagonists are the preferred treatment of hypertension in patients with Raynaud's but should be avoided in @OBJECT$ @PREDICAT$ severe @SUBJECT$ . |
Fact | preserve | 781-790 | 781-790 | T33 | treatment | TREATS | 781 | 790 | preserve | 700-713 | 700-713 | T26 | beta-blockers | PharmacologicSubstance | 700 | 713 | preserve | 800-826 | 814-826 | T32 | uncomplicated hypertension | DiseaseOrSyndrome | 800 | 826 | A26 | In the absence of contraindications, beta-blockers and diuretics are still recommended as first-line agents for treatment of uncomplicated hypertension. | 663-827 | 663 | 827 | In the absence of contraindications, @SUBJECT$ and diuretics are still recommended as first-line agents for @PREDICAT$ of @OBJECT$ . |
Fact | preserve | 1807-1811 | 1807-1811 | T117 | with | PROCESS_OF | 1,807 | 1,811 | preserve | 1812-1821 | 1812-1819 | T112 | Raynaud's | DiseaseOrSyndrome | 1,812 | 1,821 | preserve | 1798-1806 | 1798-1806 | T111 | patients | PatientOrDisabledGroup | 1,798 | 1,806 | A27 | Dihydropyridine calcium channel antagonists are the preferred treatment of hypertension in patients with Raynaud's but should be avoided in patients with severe gastroesophageal reflux disease. | 1701-1906 | 1,701 | 1,906 | Dihydropyridine calcium channel antagonists are the preferred treatment of hypertension in @OBJECT$ @PREDICAT$ @SUBJECT$ but should be avoided in patients with severe gastroesophageal reflux disease. |
Fact | preserve | 1106-1110 | 1106-1110 | T60 | with | PROCESS_OF | 1,106 | 1,110 | preserve | 1129-1148 | 1135-1148 | T57 | renal insufficiency | DiseaseOrSyndrome | 1,129 | 1,148 | preserve | 1097-1105 | 1097-1105 | T56 | patients | PatientOrDisabledGroup | 1,097 | 1,105 | A29 | ACE inhibitors may be beneficial in patients with nondiabetic renal insufficiency as well. | 1061-1157 | 1,061 | 1,157 | ACE inhibitors may be beneficial in @OBJECT$ @PREDICAT$ nondiabetic @SUBJECT$ as well. |
Fact | preserve | 1600-1613 | 1605-1613 | T96 | limb ischemia | LOCATION_OF | 1,600 | 1,613 | preserve | 1600-1604 | 1600-1604 | T89 | limb | BodyPartOrganOrOrganComponent | 1,600 | 1,604 | preserve | 1605-1613 | 1605-1613 | T90 | ischemia | DiseaseOrSyndrome | 1,605 | 1,613 | A32 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or @SUBJECT$ @PREDICAT$ @OBJECT$ have not been studied. |
Fact | preserve | 1509-1513 | 1509-1513 | T93 | with | PROCESS_OF | 1,509 | 1,513 | preserve | 1531-1562 | 1550-1562 | T86 | intermittent claudication | DiseaseOrSyndrome | 1,531 | 1,562 | preserve | 1500-1508 | 1500-1508 | T84 | patients | PatientOrDisabledGroup | 1,500 | 1,508 | A33 | Beta-blockers seem to be safe and well tolerated in patients with mild to moderate intermittent claudication, although patients with rest pain or limb ischemia have not been studied. | 1442-1642 | 1,442 | 1,642 | Beta-blockers seem to be safe and well tolerated in @OBJECT$ @PREDICAT$ mild to moderate @SUBJECT$ , although patients with rest pain or limb ischemia have not been studied. |
Uncommitted | preserve | 23-25 | 23-25 | T6 | in | TREATS | 23 | 25 | preserve | 14-22 | 14-22 | T2 | exercise | DailyOrRecreationalActivity | 14 | 22 | preserve | 26-36 | 26-36 | T3 | overweight | SignOrSymptom | 26 | 36 | A1 | Nutrition and exercise in overweight and obese postpartum women. | 0-64 | 0 | 64 | Nutrition and @SUBJECT$ @PREDICAT$ @OBJECT$ and obese postpartum women. |
Fact | preserve | 660-664 | 660-664 | T48 | with | PROCESS_OF | 660 | 664 | preserve | 665-676 | 665-676 | T41 | underweight | Finding | 665 | 676 | preserve | 695-700 | 695-700 | T43 | women | PopulationGroup | 695 | 700 | A2 | No differences were present when overweight and obese women were compared with underweight and normal weight women relative to nutrition and physical activity. | 580-751 | 580 | 751 | No differences were present when overweight and obese women were compared @PREDICAT$ @SUBJECT$ and normal weight @OBJECT$ relative to nutrition and physical activity. |
Fact | preserve | 807-824 | 819-824 | T59 | obese women | PROCESS_OF | 807 | 824 | preserve | 807-812 | 807-812 | T54 | obese | DiseaseOrSyndrome | 807 | 812 | preserve | 819-824 | 819-824 | T55 | women | PopulationGroup | 819 | 824 | A3 | Nutritional imbalances were present for overweight and obese women relative to protein and fat intake. | 752-860 | 752 | 860 | Nutritional imbalances were present for overweight and @SUBJECT$ @PREDICAT$ @OBJECT$ relative to protein and fat intake. |
Uncommitted | preserve | 23-25 | 23-25 | T6 | in | TREATS | 23 | 25 | preserve | 14-22 | 14-22 | T2 | exercise | DailyOrRecreationalActivity | 14 | 22 | preserve | 41-46 | 41-46 | T4 | obese | DiseaseOrSyndrome | 41 | 46 | A4 | Nutrition and exercise in overweight and obese postpartum women. | 0-64 | 0 | 64 | Nutrition and @SUBJECT$ @PREDICAT$ overweight and @OBJECT$ postpartum women. |
Fact | preserve | 41-63 | 58-63 | T8 | obese postpartum women | PROCESS_OF | 41 | 63 | preserve | 41-46 | 41-46 | T4 | obese | DiseaseOrSyndrome | 41 | 46 | preserve | 47-63 | 58-63 | T5 | postpartum women | PatientOrDisabledGroup | 47 | 63 | A5 | Nutrition and exercise in overweight and obese postpartum women. | 0-64 | 0 | 64 | Nutrition and exercise in overweight and @SUBJECT$ @PREDICAT$ @OBJECT$ . |
Fact | preserve | 628-639 | 634-639 | T47 | obese women | PROCESS_OF | 628 | 639 | preserve | 628-633 | 628-633 | T39 | obese | DiseaseOrSyndrome | 628 | 633 | preserve | 634-639 | 634-639 | T40 | women | PopulationGroup | 634 | 639 | A7 | No differences were present when overweight and obese women were compared with underweight and normal weight women relative to nutrition and physical activity. | 580-751 | 580 | 751 | No differences were present when overweight and @SUBJECT$ @PREDICAT$ @OBJECT$ were compared with underweight and normal weight women relative to nutrition and physical activity. |
Fact | preserve | 876-898 | 893-898 | T73 | obese postpartum women | PROCESS_OF | 876 | 898 | preserve | 876-881 | 876-881 | T61 | obese | DiseaseOrSyndrome | 876 | 881 | preserve | 882-898 | 893-898 | T62 | postpartum women | PatientOrDisabledGroup | 882 | 898 | A8 | Overweight and obese postpartum women can be encouraged to lose weight using a nutritionally balanced approach by decreasing fat and protein intake, maintaining an adequate carbohydrate intake, and increasing their folacin intake. | 861-1109 | 861 | 1,109 | Overweight and @SUBJECT$ @PREDICAT$ @OBJECT$ can be encouraged to lose weight using a nutritionally balanced approach by decreasing fat and protein intake, maintaining an adequate carbohydrate intake, and increasing their folacin intake. |
Uncommitted | preserve | 23-25 | 23-25 | T6 | in | TREATS | 23 | 25 | preserve | 14-22 | 14-22 | T2 | exercise | DailyOrRecreationalActivity | 14 | 22 | preserve | 47-63 | 58-63 | T5 | postpartum women | PatientOrDisabledGroup | 47 | 63 | A9 | Nutrition and exercise in overweight and obese postpartum women. | 0-64 | 0 | 64 | Nutrition and @SUBJECT$ @PREDICAT$ overweight and obese @OBJECT$ . |